The molecular complexity of deep vein thrombosis was preliminarily explored based on the ceRNA network, scRNA-seq and

Bao-Ze Pan1, Qing-Yu Luo1, Ming-Jun Jiang1

  • 1Department of Vascular Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, No.35, Jiefang Road, Hengyang, Hunan Province, 421001, People's Republic of China.

BMC Medical Genomics
|November 4, 2025
PubMed
Abstract

Insights

This study identifies five key genes (JAK2, CD36, TNFSF13B, TLR7, PARP9) as potential targets for deep vein thrombosis (DVT). A specific regulatory pathway involving circRNA, miRNA, and TNFSF13B is also highlighted for DVT.

Area of Science:

  • Genomics
  • Molecular Biology
  • Bioinformatics

Background:

  • Deep vein thrombosis (DVT) is a common vascular disease with complex pathogenesis and limited understanding of regulatory targets.
  • Identifying novel molecular targets is crucial for understanding DVT complications.

Purpose of the Study:

  • To identify distinctive genes associated with DVT.
  • To investigate the intricate regulatory mechanisms underlying DVT.

Main Methods:

  • Comprehensive transcriptomic analysis of circRNAs, miRNAs, and mRNAs in DVT patients and healthy controls.
  • Construction of a competing endogenous RNA (ceRNA) network model.
  • Protein-protein interaction (PPI) network analysis, AlphaFold 2 structure prediction, and Comparative Toxicogenomics Database (CTD) assessment.
  • Single-cell RNA sequencing (scRNA-seq) to determine cellular gene expression localization and pathway roles.

Main Results:

  • Identification of 406 differentially expressed circRNAs, 29 miRNAs, and 154 mRNAs.
  • Construction of ceRNA networks revealing key interactions.
  • Five hub genes (JAK2, CD36, TNFSF13B, TLR7, PARP9) identified through PPI network analysis.
  • scRNA-seq revealed distinct gene expression patterns and pathway roles across different cell types.

Conclusions:

  • JAK2, CD36, TNFSF13B, TLR7, and PARP9 are proposed as potential regulatory targets for DVT.
  • The pathway hsa_circ_0095124/hsa-miR-3074-5p/TNFSF13B is identified as a potential regulator in DVT pathogenesis.

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
282
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
335